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ShafObjective: The study objective was to establish The American Association for Thoracic Surgery (AATS) lung
cancer screening guidelines for clinical practice.
Methods: The AATS established the Lung Cancer Screening and Surveillance Task Force with multidisciplin-
ary representation including 4 thoracic surgeons, 4 thoracic radiologists, 4 medical oncologists, 1 pulmonolo-
gist, 1 pathologist, and 1 epidemiologist. Members have engaged in interdisciplinary collaborations regarding
lung cancer screening and clinical care of patients with, and at risk for, lung cancer. The task force reviewed
the literature, including screening trials in the United States and Europe, and discussed local best clinical prac-
tices in the United States and Canada on 4 conference calls. A reference library supported the discussions and
increased individual study across disciplines. The task force met to review the literature, state of clinical prac-
tice, and recommend consensus-based guidelines.
Results:Nine of 14 task force members were present at the meeting, and 3 participated by telephone. Two absent
task force members were polled afterward. Six unanimous recommendations and supporting work-up algo-
rithms were presented to the Council of the AATS at the 2012 annual meeting in San Francisco, California.
Conclusions: Annual lung cancer screening and surveillance with low-dose computed tomography is recom-
mended for smokers and former smokers with a 30 pack-year history of smoking and long-term lung cancer sur-
vivors aged 55 to 79 years. Screening may begin at age 50 years with a 20 pack-year history of smoking and
additional comorbidity that produces a cumulative risk of developing lung cancer of 5% or greater over the fol-
lowing 5 years. Screening should be undertaken with a subspecialty qualified interdisciplinary team. Patient risk
calculator application and intersociety engagement will provide data needed to refine future lung cancer screen-
ing guidelines. (J Thorac Cardiovasc Surg 2012;144:25-32)Lung cancer is the leading cause of cancer deaths in the
United States and Canada. In 2012, the National Cancer In-
stitute estimates that there will be 226,160 new cases diag-
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Abbreviations and Acronyms
AATS ¼ American Association for Thoracic
Surgery
CT ¼ computed tomography
CXR ¼ chest x-ray
GGN ¼ ground-glass nodule
LDCT ¼ low-dose computed tomography
MDT ¼ multidisciplinary team
NCCN ¼ National Comprehensive Cancer Network
NLST ¼ National Lung Screening Trial
PET ¼ positron emission tomography
Clinical Guidelines Jacobson et albetween 1996 and 2006, the incidence rates for those aged
75 years or more increased, whereas the overall incidence
rates declined.3 Only 15.9% of those diagnosed with lung
cancer survive 5 years, in part because of the association
of advanced disease stage with initial symptoms of the dis-
ease. This is a lower survival than for cancers with current
screening programs (breast, colon, and prostate).
An effective screening program that identifies early-stage
disease before symptoms would have a powerful public
health impact. Randomized trials for chest x-ray (CXR) and
sputum cytology failed to establish a role for screening to de-
tect early-stage lung cancer. The advent of single breath-hold
volumetric computed tomography (CT) scanning of the chest
at an acceptable level of radiation led to low-doseCT (LDCT)
screening trials. The increased incidence of lung cancer
coupled with increased therapeutic options and decreased
rates of infectious diseases, such as tuberculosis, in theUnited
States and Canada, also helped to increase the potential
ability for screening to decrease lung cancer morbidity and
mortality. The number of cases of lung cancer in the United
States has nearly doubled since 1980, when there were only
117,000 new cases.4 Tuberculosis peaked in 1993 with
more than 26,000 reported cases in the United States,
compared with 11,545 cases in 2009.5 Minimally invasive
thoracic surgery techniques pioneered in the 1990s now
produce the remarkably low mortality rate found in prospec-
tive trials that involve lung cancer resection by lobectomy.6
Although demographics and technology have changed,
popular opinions also have changed. The realization that to-
bacco companies deliberately added ingredients to ciga-
rettes that may have increased their addictive potential,7
and the growing population of ‘‘never smokers’’ with lung
cancer, especially among women, have changed the percep-
tion of lung cancer as a self-inflicted disease.8DEVELOPMENTAND SUCCESS OF LOW-DOSE
COMPUTED TOMOGRAPHY
These changes in our modern society led many re-
searchers to believe that the time had come to reexamine26 The Journal of Thoracic and Cardiovascular Surgemethods to screen for early-stage lung cancer. CT scan-
ning with the newer volumetric technology allowed radiol-
ogists to identify small nodules and parenchymal features
and to study the outcome of patients with these findings in
the course of nonrandomized studies in Japan and other
countries. The Early Lung Cancer Action Project under-
taken by Henschke and colleagues9 at the Weill-Cornell
Medical Center studied this technology in 1000 patients
who received both LDCT and CXR in a case-controlled
study design. They consolidated the emerging knowledge
about the imaging of early lung cancer findings that revo-
lutionized the ability to detect disease before the onset of
symptoms. The International Early Lung Cancer Action
Program was started in 1993 and screened patients aged
60 years or more with a 10 pack-year smoking history.10
This single-arm study identified 484 lung cancers in
31,567 subjects. Eighty-five percent of the cancers were
stage I, and the 10-year survival of these patients was
88%. In contrast, 8 patients with stage I lung cancer
who refused surgery had all died of disease within 5 years.
Surgical mortality in this study was 0.05% when board-
certified thoracic surgeons in cancer centers provided the
surgical care. The International Early Lung Cancer Action
Program developed a robust care model; however, im-
proved survival could not be used as a surrogate for de-
creased mortality.
The National Cancer Institute sponsored a randomized
phase III National Lung Screening Trial (NLST) that, for
the first time, provided level I evidence that LDCT screen-
ing can reduce lung cancer–specific mortality. Between Au-
gust 2002 and April 2004, 53,454 individuals at high risk for
lung cancer enrolled for 3 annual screens, with half receiv-
ing LDCT and half receiving CXR; all individuals then re-
ceived follow-up through 2009 before early termination of
the trial, when a 21% reduction in lung cancer–specific
mortality was reached in the LDCT arm.11 This was
achieved by a trial designed to have 90% power to detect
this level of difference in the most cost-effective manner
possible, using only 3 screens of a very high-risk population
during the years leading up to the peak age range for lung
cancer. The NLST enrolled smokers and former smokers,
who quit smoking less than 15 years earlier, between 55
and 74 years of age with at least a 30 pack-year history of
cigarette smoking. Subjects were excluded if they had a his-
tory of lung cancer, a CT scan of the chest within 18 months
of enrollment, hemoptysis, or an unexplained weight loss
more than 6.8 kg (15 lbs).12
Three consecutive annual screens provided a prevalence
screen and 2 annual screens. Longer duration of screening
was not economically viable where each annual round of
screen generated 26,723 LDCT scans and an equal number
of CXR examinations. Positive screens were obtained in
24.2% of the LDCT arm and 6.9% of the CXR arm. Ad-
verse events, including those from needle biopsy andry c July 2012
Jacobson et al Clinical Guidelinessurgical resection, occurred in 1.4% of those in the LDCT
arm and 1.6% in the CXR arm.
The surgical mortality of less than 1% among those pa-
tients who underwent surgical resection of lung cancer is vi-
tal to the practical success of lung cancer screening in
clinical practice. The NLST secondary analyses will con-
tinue to provide additional data and insight over the coming
years, as will smaller prospective randomized trials accru-
ing individuals to LDCT protocols in Europe. The NLST
has the power to provide convincing evidence in favor of
lung cancer screening at this time. Sufficient data are cur-
rently available to provide guidelines in favor of lung cancer
screening in North America.TABLE 1. Recommendations of The American Association for
Thoracic Surgery Task Force for Lung Cancer Screening and
Surveillance in the United States and Canada
1. Annual lung cancer screening with LDCT for smokers and former
smokers with 30 pack-year history of smoking from ages 55 to 79 y.
2. Long-term lung cancer survivors should have annual LDCT to detect
second primary lung cancer until the age of 79 y.
3. Annual lung cancer screening with LDCT for smokers and former
smokers aged 50 to 79 y with a 20 pack-year history of smoking and
additional comorbidity that produces a cumulative risk of developing
lung cancer of  5% over the following 5 y.
4. Lung cancer screening and successful treatment of early-stage lung
cancer by a subspecialty qualified team, including thoracic surgeons,
thoracic radiologists, pulmonologists, oncologists, and pathologists.
5. Develop a web-based application for patient self-risk assessment.
6. Continue AATS engagement with other specialty societies to develop
and refine future screening guidelines.
LDCT, Low-dose computed tomography; AATS, American Association for Thoracic
Surgery.MATERIALS AND METHODS
With the announcement of mortality benefit for LDCT in July 2011,
The American Association for Thoracic Surgery (AATS) councilors con-
sidered how best to translate the landmark work of the NLST into work-
able clinical guidelines for screening at-risk patients. In addition, thoracic
surgeons sought to provide the dose-reduction benefits of LDCT to the
more than 400,000 long-term lung cancer survivors in the United States
and Canada. Co-chairs Francine Jacobson, MD, MPH, a thoracic radiol-
ogist, and Michael Jaklitsch, MD, a thoracic surgeon, were appointed and
asked to create a committee with 12 to 20 members who would recom-
mend lung cancer screening and surveillance guidelines to the Council
by April 2012. The co-chairs created an interdisciplinary list of stake-
holders whose academic careers have been dedicated to decreasing the
morbidity and mortality of lung cancer through the early identification
and successful treatment of the disease. The selection process was mul-
tifactorial and included individuals who have been involved in a wide va-
riety of lung cancer and lung screening trials. Invitations were extended
to more than 20 key stakeholders who were also invited to nominate
others to serve on the task force, and 14 engaged with exceptional
commitment. Task force members represent the specialties of thoracic
surgery, pulmonary medicine, radiology, oncology, pathology, and
epidemiology. Members also have related cross-disciplinary interests,
and several have led key projects leading up to this milestone in the his-
tory of lung cancer, including various lung cancer screening projects over
the past 20 years. Several members have equally strong credentials in at
least one additional specialty, increasing perspective across disciplines
with direct representation of surgery (4), pulmonary medicine (1), radiol-
ogy (4), oncology (4), pathology (1), and epidemiology (1). The group
provides care in a variety of settings in the United States and Canada.
International participation was valued for perspective and coordination
of intersociety dialog through the International Society for the Study of
Lung Cancer.
Charge to Committee
In September 2011, the task force was charged to establish guidelines
for lung cancer screening and surveillance of lung cancer survivors for de-
velopment of second lung cancer in the North American population. By ac-
knowledging that guidelines may differ for different populations, the group
set out to develop detailed guidelines and algorithms for the identification,
workup, and treatment of screen-identified lung cancer. The interdisciplin-
ary organizational structure chosen for this task force was designed to sup-
port the unique central voice of the AATS and to serve other professional
societies and the public. The task force was asked to structure their recom-
mendations to be relevant for up to 7 to 10 years from now, when molecular
epidemiology is likely to be established and biomarkers may play a more
important role than LDCT. The dialog is thus about early identification
of lung cancer through a multidisciplinary process that can dynamicallyThe Journal of Thoracic and Cadapt to rapidly changing and increasingly personalized delivery of health
care within a structured framework.
Committee Process
Four conference calls were used to explore differences in local clinical
practice patterns and to both collect and discuss the extensive and dynam-
ically changing literature bearing on decisions regarding clinical imple-
mentation of LDCT in the United States and Canada. A 1-day meeting
was then held in Boston to review the literature, discuss the implications,
and formally vote on recommendations to present to the Councilors of
the AATS. A system was prepared in advance to allow voice to significant
dissenting opinions and rank strength of evidence separately from strength
of recommendation. All meetings had agendas circulated beforehand and
minutes circulated afterward. Initial conference calls were recorded to im-
prove transcription of notes. The AATS provided access to selected litera-
ture for online review. Because of the dynamic nature of the literature in
this field, the task force was able to include the National Comprehensive
Cancer Network (NCCN) 2012 guidelines13 and an actuarial analysis of
cost-benefit in preparing the task force recommendations.14 The task force
used the process begun with the NCCN guidelines to broaden the recom-
mendation for screening in the United States to extend the findings of
the NLST as a research study to long-term clinical health care.RESULTS
Six unanimous recommendations accompanied by the al-
gorithms published as part of the AATS guidelines were
presented to the Councilors of the AATS at the 2012 annual
meeting. These 6 recommendations were accepted by the
AATS (Table 1).
(1) Annual lung cancer screening with LDCT is recom-
mended for smokers and former smokers with a 30 pack-
year history of smoking from age 55 to 79 years. This
recommendation is based on NLST, age as an independent
risk factor, and life expectancy. Furthermore, there is no sci-
entific evidence to stop screening after 3 annual screens. The
divergence of survival graphs in theNLST during the screen-
ing period followed by more parallel course of survival
curves during the observationperiod suggests that themortal-
ity reduction would have exceeded 20% if annual screeningardiovascular Surgery c Volume 144, Number 1 27
Clinical Guidelines Jacobson et alexaminations had been continued. The task force therefore
recommended increasing the upper age limit from 74 years,
the median age for lung cancer incidence, to 79 years based
on the life expectancy at age 74 years, on average in the
United States, of 78.6 years. Thus, screening should add
7 years to life expectancy. It is possible that the extremely
elderly represent a different population who may warrant
individual case consideration for screening based on health
and functional status. Screening should not be offered to in-
dividuals for whom adequate treatment cannot be offered be-
cause of comorbidity or functional status, regardless of age.
(2) Individuals treated for lung cancer should receive sur-
veillance for recurrent disease and for new lung cancer. The
initial surveillance beyond the perioperative period is de-
signed primarily to identify recurrent disease. By 4 to 5
years after therapy, the purpose of CT follow-up is to pro-
vide surveillance to detect new primary lung cancer. There-
fore, these patients should have annual LDCT to detect new
primary lung cancer until the age of 79 years.
(3) The incorporation of smaller risk factors will become
more objective over the next several years. The NCCN
guidelines provide a second-tier recommendation for the
addition of a risk factor such as chronic obstructive pulmo-
nary disorder combined with younger age and less smoking
history. The task force strongly encourages the use of risk
calculators to assist in creating a more quantified approach
to this extension. Beginning annual lung cancer screening
with LDCT for smokers and former smokers at age 50 years
with a 20 pack-year history of smoking should be consid-
eredwhen the additional comorbidity produces a cumulative
risk of developing lung cancer of 5% or more over the
following 5 years. Screening of a woman may be deferred
before menopause.
(4) Realizing the potential for lung cancer screening and
successful treatment of early-stage lung cancer by a multi-
disciplinary team (MDT) requires active participation by
subspecialty-qualified thoracic surgeons, thoracic radiolo-
gists, pulmonologists, oncologists, and pathologists. The
perspective of each specialty is required to establish and
maintain a local implementation of lung cancer screening
guidelines. The sharing of vocabulary, emerging literature,
and patient outcomes across specialties is critical for
smooth functioning and further development of a screening
program. Thoracic surgeons trained in minimally invasive
capabilities, such as video-assisted thoracoscopic surgery,
will maintain the low operativemortality for invasive proce-
dures. We further recommend that volumetric analysis be
used, when possible, to guide decisions.
(5) The task force recommends the development of
a web-based application for handheld devices to allow pa-
tients to access educational information, assess personal
risk of lung cancer, and potentially allow voluntary anony-
mous data collection about the population risk of lung can-
cer in the United States and Canada. This approach would28 The Journal of Thoracic and Cardiovascular Surgesupport the quantitative approach recommended for com-
bining risks in a manner that can be updated easily as
more data bearing on such decisions become available.
(6) The AATS has established engagement across spe-
cialties that needs to be maintained to pursue the research
that is still needed to answer the myriad of questions that
have not been answered and those that have not been asked
regarding lung cancer screening. Through ongoing engage-
ment with other specialty societies and International Soci-
ety for the Study of Lung Cancer, the AATS will maintain
the central role for thoracic surgeons in the diagnosis and
treatment of lung cancer.
Clinical Lung Cancer Screening
The task force identified more similarities than differ-
ences between different trials and different communities
in the United States and Canada. The following material
provides practical strategies intended to serve as starting
points for local implementation guided by the local MDT.
The MDT may mirror the task force membership with
participation by the specialists regularly involved in the di-
agnosis and treatment of early lung cancer in the commu-
nity. Representation should include subspecialty-trained
radiologists, surgeons, internists, and pathologists who pro-
vide patient care and follow the scholarly progress regarding
lung cancer screening within their specific disciplines.
Regular conferences allow for input from additional
perspectives and encourage themaintenance and dissemina-
tion of outcomes within local communities. The MDT is
most able to maximize smoking cessation within the context
of lung cancer screening and interface with grass-roots ad-
vocacy groups and professional societies. This structure
will minimize the time required to implement changes that
will evolve through emerging data analysis and develop-
ment of alternative screening methods based on biomarkers.
Type of Scan
LDCT should be performed using multidetector CT scan
technology with the lowest dose that will provide adequate
visualization and measurement of small lung nodules (aver-
age effective dose in the NLST was 1.5 mSv). The NLST
scanning protocol is technologically feasible in general
community settings. All machines should meet the techni-
cal standards of the American College of Radiology. Dose
modulation may be used. Subcentimeter slices are desirable
for measurement by volumetric software when possible;
however, 1- to 2-mm contiguous images are acceptable.
The value to patient health from LDCT is broader than
just the identification of lung cancer. Emphysema and other
lung diseases should be assessed. Coronary calcifications
are clearly seen on most scans and should be reported. Inci-
dental findings that have contributed to the all-cause mortal-
ity benefit found by NLST include renal cell carcinomas
and aortic aneurysms.ry c July 2012
FIGURE 1. AATS lung cancer screening guidelines for solid nodules on low-dose computed tomography (LDCT). PET/CT, Positron emission tomography/
computed tomography.
Jacobson et al Clinical GuidelinesManagement of Indeterminate Solid Nodules
Indeterminate solid nodules are managed by size
(Figure 1). Baseline LDCT is negative if no nodules are pres-
ent. It is also negative when only solid nodules 4 mm or less
in diameter are present. Tiny solid nodules are frequent find-
ings and unlikely to represent early lung cancer, particularly
if they do not increase in size between the prevalence and
first incidence screens. These individuals should continue
with routine annual LDCT screening until age 79 years.
Solid nodules with a mean diameter between 4 and 6 mm
are considered indeterminate and should have a repeat
LDCT in 6 months. In the case of stable or smaller nod-
ule(s), a screen is then considered negative, and these indi-
viduals should then continue with annual LDCT screening
up to age 79 years.
Solid nodules with a mean diameter of 6 to 8 mm also
should be considered indeterminate with a repeat LDCT
in 3 months. If the nodule remains solid and decreases in
size, the screen is reclassified as negative and the individual
should return to annual LDCT screening up to age 79 years.
A stable nodule in this size range (mean diameter> 6-8
mm) is still considered an indeterminate nodule and should
have a repeat LDCT in 6 to 9 months (9 months coincides
with annual screen). If the subsequent LDCT scan reveals
a decrease in diameter or stable mean diameter on the sec-
ond scan, the screen is classified as a negative result and the
patient should return to annual LDCT up to age 79 years. If
there is a further increase in the nodule on the second
LDCT, this is considered a positive screen with consider-
ation of biopsy and treatment (preferably surgical removal).
Solid nodules with a mean diameter greater than 8 mm
are classified as screen positive and should lead to referral
to the specialists who oversee the workup and management
of lung cancer in the community. A positron emission to-
mography (PET)/CT scan may obviate the need for surgery
if the scan suggests a low suspicion of malignancy. In theThe Journal of Thoracic and Cface of such a low suspicion due to a PET/CT scan, how-
ever, a repeat LDCT scan should be obtained in 3 months,
and increase in size or geometry should then be interpreted
as a positive screen with surgical intervention. If no PET/
CT is obtained, or a PET/CT is suspicious for malignancy,
the patient should be referred for surgical staging and resec-
tion. The finding of a solid endobronchial lesion on an
LDCT scan should lead to referral to a specialist for
bronchoscopy.
Ground-Glass Nodules
Ground-glass nodules (GGNs) are well-demarcated nod-
ules of subtly increased attenuation through which vessels
can still be separately visualized that require a separate algo-
rithm for workup (Figure 2). GGNs are also sometimes de-
scribed as nonsolid nodules. Homogeneous GGN may
represent atypical adenomatous hyperplasia when 5 mm or
less and adenocarcinoma in situ when larger. In the adenocar-
cinoma disease spectrum, the development of solid compo-
nents increases concern for invasive malignancy. These
most worrisome nodules may be referred to as part-solid.
The determination of worrisome changes in such nodules is
complex because of potential changes that may increase or
decrease overall size of a GGN and size of solid component.
Increasing density alone may indicate progressive disease.
Inflammatory processes can also cause ground-glass
opacities. Early pneumonia and pneumonia in immune-
compromised hosts may have ill-defined ground-glass
opacities with or without areas of more solid-appearing
opacity and consolidation.
The AATS recommends consistent application of size
guidelines, such as those developed by the Fleischner Soci-
ety, for management of ground-glass opacities discovered
on LDCT at baseline scan or during an annual LDCT
screening examination within the previously described
screening populations.ardiovascular Surgery c Volume 144, Number 1 29
FIGURE 2. AATS lung cancer screening guidelines for ground-glass nodule. LDCT, Low-dose computed tomography.
Clinical Guidelines Jacobson et alAn increase in the size of a GGN that was originally less
than 5 mm or a change in a GGN such as the development of
a solid component should increase consideration of surgical
resection. If surgical resection is not practical for a particu-
lar small changing GGN, a repeat LDCT should be obtained
in 3 to 6 months. If the lesion is stable, continued screening
with annual LDCT should be resumed up to age 79 years for
high-risk populations. If the repeat LDCT scan shows con-
tinued growth, biopsy or surgical excision may become
feasible.
For GGNs between 5 and 10 mm on baseline LDCT, a re-
peat LDCT should be performed in 6 months. Stable abnor-
malities would then revert to annual LDCT scans, whereas
an increase in size or development of a solid component
should lead to referral to a lung cancer specialist and consid-
eration of surgical excision.
GGNs greater than 10 mm in mean diameter should
have a repeat LDCT scan in 3 to 6 months, if not resected.
If the lesion is considered stable, and not regressing in size,
considerations include biopsy, surgical excision, and repeat
LDCT in 6 to 12 months. GGNs greater than 10 mm inFIGURE 3. AATS lung cancer screening guidelines for new nodule on low-dos
computed tomography.
30 The Journal of Thoracic and Cardiovascular Surgemean diameter that increase in size or develop a part-
solid component on repeat scan should undergo surgical
excision.
Workup of Positive Annual Low-Dose Computed
Tomography Scans
If a new nodule is detected on an annual LDCT screen,
further workup depends on the character and size of the le-
sion, and suspicion of infection (Figure 3).
If a new solid nodule does not show benign characteris-
tics, then size mandates further workup and the algorithm
presented in Figure 1 should be followed. The probability
of malignancy in a new GGN without suspicion for
infection also depends on size and should be worked up fol-
lowing the algorithm presented in Figure 2.
New nodules detected by LDCT scan that may be due to
infection or inflammation should be treated with antimicro-
bials and then have a repeat LDCT scan in 1 to 2 months. If
the inflammatory process is resolving, but a component re-
mains, then repeat radiographic imaging should continue
until complete resolution of this inflammatory process.e computed tomography (LDCT). PET/CT, Positron emission tomography/
ry c July 2012
Jacobson et al Clinical GuidelinesHigh-risk populations with resolved lung inflammation
should return to annual LDCT screening up to age 79 years.
GGN or other potentially inflammatory-appearing opac-
ity on LDCT scan requires follow-up LDCT within 3
months; if the nodule increases in size, the screen is consid-
ered positive.A PET/CT scan should be considered, and sur-
gery may be obviated by low suspicion of cancer on that
scan, although adenocarcinoma can have little or no fluoro-
deoxyglucose avidity. An LDCT scan should be obtained in
3 months after such PET/CT scan. Further enlargement of
the nodule on LDCT is considered a positive screen andwar-
rants surgical excision. A CT scan obtained for attenuation
correction of PET scan provides a significantly lower-
quality scan than LDCT. Low-level fluorodeoxyglucose
avidity is characteristic of both inflammation and relatively
indolent adenocarcinoma, limiting its usefulness for differ-
entiation of benign and malignant diseases.
DISCUSSION
Reducing the radiation dose for CT scanning has become
a central focus for scanner manufacturers and radiologists. It
is likely that in the near future, new methods of reconstruct-
ing the images will provide significantly lower doses than
even the 1.5 total body equivalent dose estimates for
NLST. Over the decade since the NLST opened, slice thick-
nesses and scan times have decreased further. Population
screening using thin-section LDCT requires a labor-
intensive review process by the radiologist. Tiny nodules, be-
low the threshold of a positive screen by size (<4 mm in
diameter), may be inconsistently imaged and inconsistently
identified, particularly when multiple tiny nodules are pres-
ent. The subjective and semiquantitative measurement of
tiny nodules by radiologists using eye and electronic calipers
varies by more than one doubling time between 4 and 5 mm.
Part-solid nodules and GGNs also pose challenges in the
assessment of growth with critical implications for clinical
decision-making. Volumetric nodule measurements are to
be preferred and should be provided when possible. As this
and computer-aided diagnosis become more widely avail-
able, they should be incorporated into thework-flow for rou-
tine interpretation of LDCT. Standardization of reporting, as
donewith Breast Imaging-Reporting andData System (BIR-
ADS) for mammography, also deserves encouragement.
Radiation Risk
The radiation exposure from LDCT is an acceptably
small risk for high-risk populations. The average effective
dose per scan in the NLST trial was 1.5 mSv.11 The Amer-
ican Association of Physicists in Medicine December 13,
2011, position statement on radiation risks from medical
imaging procedures states, ‘‘Risks of medical imaging at ef-
fective doses below 50 mSv for single procedures or 100
mSv for multiple procedures over short time periods are
too low to be detectable, and may be nonexistent.’’15The Journal of Thoracic and CPatient Requirements for Screening
Approximately 7 million of 94 million current and for-
mer smokers in the United States meet the NLST criteria
for highest risk screening.13 More than 75% of the positive
screening tests resulted in additional testing, most fre-
quently by repeat imaging. Less than 10% of the tests re-
quired an invasive procedure for further workup.
Screening should not be performed for individuals at el-
evated risk who do not have the physical reserve required
for appropriate treatment. Intervention risks are related to
performance status, and long-term survival is negatively af-
fected by poor constitution. Performance status and lung
function will be used to determine on an individual basis
when to stop lung cancer screening. In the future, the use
of ablation for early lung cancer may increase treatment po-
tential for elderly patients. Extremely elderly patients who
are well may also benefit from continued screening beyond
age 79 years on an individual basis.
Cost-Effectiveness of Screening
In the NLST trial, 320 screens were necessary to detect 1
cancer. In other words, $35,000 can detect and treat the sin-
gle cancer, and reassure 319 others that they do not have
lung cancer despite their pretest risk.
The most recent estimate of the cost and benefit of annual
lung cancer screening offered as a commercial insurance
benefit for high-risk Americans aged 50 to 64 years found
a screening cost of $1 per insured member per month in
2012 dollars.14 Furthermore, the cost per life-year saved
would be less than $19,000. This compares favorably to
cost per life-year saved in breast ($31,000-$52,000), co-
lon ($19,000-$29,000), and cervical cancers ($50,000-
$75,000). The authors concluded that lung cancer screening
for high-risk patients aged 50 years and more with 30 pack-
years smoking was high-value coverage.
Future Directions
In addition to the 20% decrease in lung cancer–specific
mortality, the NLST found a 7% decrease in all-cause mor-
tality. From the perspective of the individual patient being
cared for by his or her physician, LDCT provides additional
valuable information regarding health and disease processes,
including diffuse lung diseases and cardiovascular disease.
Emphysema, identified by screening, is an independent risk
factor for the development of lung cancer. As phenotypes
of chronic obstructive pulmonary disorder are identified by
the COPDGene study, it is reasonable to expect greater un-
derstanding of why particular patients develop lung cancer
while others with the same smoking history do not. In the fu-
ture, this may lead to differences in recommendations for
screening based on individualized risk. The clinical LDCT
goal is the early identification of lung cancer that enables suc-
cessful treatment with the least morbidity and risk of mortal-
ity for the individual patient. In the future, we anticipate theardiovascular Surgery c Volume 144, Number 1 31
Clinical Guidelines Jacobson et aluse of a biomarker in urine or blood as the primary popula-
tion screen. It may remain valuable to obtain a single baseline
reference LDCT scan to validate the initial negative bio-
marker and serve as a comparison CT in the case of a subse-
quent positive screening test result.
Volumetric analysis may be a more accurate way to radio-
graphically sort suspicious from nonsuspicious nodules.
This technology is currently being used in the Dutch-
Belgium Lung Cancer Screening Trial (NELSON). Mea-
surements are performed using a volumetric analysis with
a lower limit of 50mm3 (4.6mmdiameter) identifying ‘‘neg-
ative’’ nodules. A ‘‘positive’’ nodule is any finding greater
than 500 mm3 (>9.8 mm diameter). Between these 2 param-
eters, nodules are considered indeterminate, and repeat vol-
umetric studies are particularly useful at identifying rapidly
growing nodules that are then considered ‘‘positive.’’ This
may prove useful in the near future, although the penetrance
of this technology into the community is not yet sufficient to
be strongly advocated by the AATS at this time.
Prediction models of risk of developing lung cancer over
the next 5 years are currently available: the Bach model
based on data from Beta-Carotene and Retinol Efficacy
Trial, the Spitz model based on data from an ongoing
case-control study, and the Liverpool Lung Project based
on a case-control study in Liverpool, England. At this
time, these do not provide complete data for important sub-
populations in North America. It is probable that a clinical
prediction rule could be converted to a smart phone ‘‘App’’
that would allow patients to calculate their risk of develop-
ing lung cancer. This would be a way to enable individual
patients to assess their own risk and to identify populations
who would most benefit from screening. For now, these
models lack sufficient accuracy for routine use but are ex-
pected to be refined with additional data collection.
It is highly likely that LDCT will be augmented or re-
placed as the primary lung cancer screening modality by
a biomarker test, such as sputum, urine or blood, or even
breath condensate as a potential primary population screen.
It may remain valuable to obtain a single baseline reference
CT scan to validate the initial negative biomarker and serve
as a comparison CT in the case of a subsequent positive
screening test result.
Biomarkers
There have been a number of serum biomarkers (from tra-
ditional carcinoembryonic antigen/cancer antigen 125 to mi-
croRNA) that have been used for potential screening
without a large population validation. Methylation of certain
genes, microRNA, and glycosylation of proteins have been
detected in sputum and urine. A number of samples have
been collected within the NLST, and several biomarkers are
being analyzed within this study with future publications ex-
pected that may refine the screeningmethod. To positively af-
fect screening strategies, we need to be able to determine not32 The Journal of Thoracic and Cardiovascular Surgeone particular sample or pathway, but a global and systematic
approach.
CONCLUSIONS
New data analyses will continue to update the view of
professionals actively engaged in this dialog over the com-
ing months and years. The issues that direct public health
and societal allocation of resources will be important but
we have entered a new era for the early detection of lung
cancer. The recommendations of the AATS task force are
offered with the intent to support individualized decision
making based on the literature and best practices for the
early diagnosis and treatment of lung cancer in the United
States and Canada.
We would like to acknowledge Matt Eaton, Director of Admin-
istration, The American Association for Thoracic Surgery, for his
invaluable assistance and Mark Jacobson for graphics.
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